Table 7. Rucaparib as maintenance therapy, monotherapy, and combination therapy.

PFS: progression-free survival; OS: overall survival; ORR: objective response rate; BRCA: breast cancer-associated; PALB2: partner and localizer of BRCA2; HRD: homologous recombination deficiency

Clinical trial	Phase	N	Study objective	Germline mutations	Somatic mutations	PFS	OS	ORR
Rucaparib as maintenance therapy
NCT03140670 [50]	II	24	Evaluate maintenance in pancreatic adenocarcinoma not progressing for at least 16 weeks of platinum treatment	13 germline BRCA2, 3 germline BRCA1, 2 germline PALB2	1 somatic BRCA2	9.1	N/A	37%
Rucaparib as monotherapy
NCT02042378 [51] RUCAPANC	II	19	Evaluation monotherapy in advanced pancreatic cancer patients with germline or somatic BRCA patients who received upto two lines of prior chemotherapy.	12 germline BRCA2, 4 germline BRCA1	3 somatic BRCA2	Halted enrollment (ORR of 16% ) in view of insufficient response rate among the first 15 patients
Rucaparib with chemotherapy
NCT03337087 [52]	Ib/II	N/A	Evaluate safety and preliminary efficacy of liposomal irinotecan and fluorouracil with rucaparib in patients with metastatic gastrointestinal cancers including pancreatic cancer	Plan to evaluate response based on HRD mutations	Currently enrolling
NCT04171700 [53] LODESTAR	II	N/A	Evaluating rucaparib therapy in HRD deficient solid tumors including pancreatic cancer	HRD-deficient tumors	Currently enrolling
Rucaparib in combination with targeted therapy
NCT02711137 [54]	I/II	N/A	Safety and BET inhibitor as single agent and in combination with multiple interventions including rucaparib in advanced malignancy pts	Study is currently terminated in view of safety issues.